Brind.
  1. AbbVie and others are managing drug exclusivity, seeking next-gen immunology pipeline growth, and competing for market share.
  2. M&A activity is driving sector recovery.
  3. AbbVie reached a definitive agreement valued at $10.9 billion with Apogee Therapeutics.

The acquisition of Apogee Therapeutics by AbbVie is expected to close in Q3.

1 report, 1 independent Updated Jul 31
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

The acquisition of Apogee Therapeutics by AbbVie is expected to close in Q3.

Who's involved

What this event is mainly about
AbbVie

Keep exploring

Part of

AbbVie reached a definitive agreement valued at $10.9 billion with Apogee Therapeutics. All 1 developments

Within AbbVie and others are managing drug exclusivity, seeking next-gen immunology pipeline growth, and competing for market share.

The entities involved

Coverage

Newest first; wire copies grouped